Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease
NCT03196427Phase 2Completed
- Sponsor
- Takeda
- Start
- Jul 2018
- Primary completion
- Apr 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of vedolizumab in ulcerative colitis (UC), Crohn's disease, sponsored by Takeda. Started Jul 2018; status: completed.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03196427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196427.